KACTUS Biosystems
Founded Year
2018Stage
Series B | AliveTotal Raised
$38.9MLast Raised
$27.72M | 1 yr agoAbout KACTUS Biosystems
KACTUS Biosystems is a biotechnology company focused on delivering protein and antibody products and technologies for immune therapy and IVD customers. The company develops a functional recombinant protein production platform called Structure Aided design and Multiplex Screening (SAMS), applying both bioinformatics and computer simulations to construct 3D protein models. It was founded in 2018 and is based in Shanghai, China.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Latest KACTUS Biosystems News
Mar 3, 2021
The developers are seeking a 20-year, $19 million payment-in-lieu-of-taxes (PILOT) for the $61 million, six-story phase at 47 Keel Ave.
KACTUS Biosystems Frequently Asked Questions (FAQ)
When was KACTUS Biosystems founded?
KACTUS Biosystems was founded in 2018.
Where is KACTUS Biosystems's headquarters?
KACTUS Biosystems's headquarters is located at 4th Floor, Area 8A, No. 188 Xinjun Ring Road, Pujiang High-tech Park, Shanghai.
What is KACTUS Biosystems's latest funding round?
KACTUS Biosystems's latest funding round is Series B.
How much did KACTUS Biosystems raise?
KACTUS Biosystems raised a total of $38.9M.
Who are the investors of KACTUS Biosystems?
Investors of KACTUS Biosystems include New Alliance Capital, Abon, Guofang Investment, Lingang Lanwan Fund, Divine Capital and 7 more.
- Predict emerging trends
- See competitors' playbooks
- Stalk the smart money
- Identify tomorrow's challengers
- Spot growing industries
- Kill analyst data work
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.
